Georgia Deliyannis,Chinn Yi Wong,Paula Ellenberg,Tim Smith,Marianne Gillard,Ester Lopez,Julie McAuley,Chee Wah Tan,Weiguang Zeng,Mason Littlejohn,Runhong Zhou,Jasper Fuk-Woo Chan,Richard Bowen,Elizabeth Vincan,Joseph Torresi,Katherine Kedzierska,Kanta Subbarao,Marc Pellegrini,Trent Munro,Terry Nolan,Steven Rockman,Nicholas A. Gherardin,Samantha L. Grimley,James P. Cooney,Samuel J. Redmond,Kathryn C. Davidson,Francesca L. Mordant,Jing J. Wang,Zhi-wei Chen,Airn E. Hartwig,Jason M. Mackenzie,Colin W. Pouton,Tom P. Gordon,Lin-fa Wang,Stephen J. Kent,Adam K. Wheatley,Sharon R. Lewin,Amy W. Chung,David C. Jackson,Damian F.J. Purcell,Dale I. Godfrey

Abstract:BACKGROUND: The SARS-CoV-2 global pandemic has fuelled the generation of vaccines at an unprecedented pace and scale. However, many challenges remain, including: the emergence of vaccine-resistant mutant viruses, vaccine stability during storage and transport, waning vaccine-induced immunity, and concerns about infrequent adverse events associated with existing vaccines.METHODS: We report on a protein subunit vaccine comprising the receptor-binding domain (RBD) of the ancestral SARS-CoV-2 spike protein, dimerised with an immunoglobulin IgG1 Fc domain. These were tested in conjunction with three different adjuvants: a TLR2 agonist R4-Pam2Cys, an NKT cell agonist glycolipid α-Galactosylceramide, or MF59® squalene oil-in-water adjuvant, using mice, rats and hamsters. We also developed an RBD-human IgG1 Fc vaccine with an RBD sequence of the immuno-evasive beta variant (N501Y, E484K, K417N). These vaccines were also tested as a heterologous third dose booster in mice, following priming with whole spike vaccine.FINDINGS: Each formulation of the RBD-Fc vaccines drove strong neutralising antibody (nAb) responses and provided durable and highly protective immunity against lower and upper airway infection in mouse models of COVID-19. The 'beta variant' RBD vaccine, combined with MF59® adjuvant, induced strong protection in mice against the beta strain as well as the ancestral strain. Furthermore, when used as a heterologous third dose booster, the RBD-Fc vaccines combined with MF59® increased titres of nAb against other variants including alpha, delta, delta+, gamma, lambda, mu, and omicron BA.1, BA.2 and BA.5.INTERPRETATION: These results demonstrated that an RBD-Fc protein subunit/MF59® adjuvanted vaccine can induce high levels of broadly reactive nAbs, including when used as a booster following prior immunisation of mice with whole ancestral-strain spike vaccines. This vaccine platform offers a potential approach to augment some of the currently approved vaccines in the face of emerging variants of concern, and it has now entered a phase I clinical trial.FUNDING: This work was supported by grants from the Medical Research Future Fund (MRFF) (2005846), The Jack Ma Foundation, National Health and Medical Research Council of Australia (NHMRC; 1113293) and Singapore National Medical Research Council (MOH-COVID19RF-003). Individual researchers were supported by an NHMRC Senior Principal Research Fellowship (1117766), NHMRC Investigator Awards (2008913 and 1173871), Australian Research Council Discovery Early Career Research Award (ARC DECRA; DE210100705) and philanthropic awards from IFM investors and the A2 Milk Company.

Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge

Protection Against SARS-CoV-2 Infection by a Mucosal Vaccine in Rhesus Macaques.

An Adenovirus-Vectored COVID-19 Vaccine Confers Protection from SARS-COV-2 Challenge in Rhesus Macaques.

A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses

A Dual‐Adjuvanted Parenteral‐Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS‐CoV‐2 in Mice

Mucosal prime-boost immunization with live murine pneumonia virus-vectored SARS-CoV-2 vaccine is protective in macaques

Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge

A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques

Combining Intramuscular and Intranasal Homologous Prime-Boost with a Chimpanzee Adenovirus-Based COVID-19 Vaccine Elicits Potent Humoral and Cellular Immune Responses in Mice.

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera

A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice

Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates

An Intranasally Administrated SARS-CoV-2 Beta Variant Subunit Booster Vaccine Prevents Beta Variant Replication in Rhesus Macaques

Enhanced mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant

Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants